BioCentury | May 5, 2003
Company News

Omnia Biologics Inc. management update

...Inc. , Rockville, Md. Business: Infectious diseases Hired: Dale VanderPutten as CEO, formerly CSO of DirectGene Inc. WIR...
BioCentury | Jul 22, 2002
Company News

DirectGene, GenVec deal

...cancer therapeutics based on selectively replicating adenovectors. The deal combines GNVC’s targeted adenovector technology with DirectGene’s...
...royalties. DirectGene will have rights to use the targeting technology with three of DirectGene’s adenovectors. DirectGene Inc....
BioCentury | Jul 15, 2002
Company News

GenVec, DirectGene cancer deal

...cancer therapeutics based on selectively replicating adenovectors. The deal combines GNVC's targeted adenovector technology with DirectGene's...
...royalties. DirectGene (Annapolis, Md.) will have rights to use the targeting technology with three of DirectGene's...
BioCentury | Jan 28, 2002
Company News

DirectGene, Intradigm deal

...combines Intradigm's gene vector technology with DirectGene's tumor-selective promoter technology. DirectGene will provide research funding. DirectGene Inc....
BioCentury | Jan 25, 2002
Company News

Intradigm, DirectGene cancer R&D deal

...Intradigm (Rockville, Md.) and DirectGene (Annapolis, Md.). partnered to develop cancer products. The deal combines Intradigm's...
...develop cancer products. The deal combines Intradigm's gene vector technology with DirectGene's tumor-selective promoter technology. DirectGene...
BioCentury | Feb 5, 2001
Finance

Ebb & Flow

...E 12.5 on the week after announcing a deal to manufacture clinical grade batches of DirectGene's...
BioCentury | Feb 5, 2001
Finance

Ebb & Flow

...E 12.5 on the week after announcing a deal to manufacture clinical grade batches of DirectGene's...
BioCentury | Feb 5, 2001
Company News

Crucell, DirectGene deal

...CRXL will manufacture clinical grade batches of DirectGene’s adeno-viral therapy for prostate cancer, which is expected...
...agreement giving DirectGene access to the PER.C6 technology. Crucell N.V. (Euronext:CRXL; CRXL), Leiden, the Netherlands DirectGene Inc....
BioCentury | Jan 31, 2001
Company News

First PER.C6 production deal for Crucell

...Gene and antibody company Crucell (CRXL; Euronext:CRXL) will manufacture clinical grade batches of DirectGene's compound to...
...its PER.C6 human cell line production platform. Last year, CRXL entered a license agreement giving DirectGene...
Items per page:
1 - 9 of 9
BioCentury | May 5, 2003
Company News

Omnia Biologics Inc. management update

...Inc. , Rockville, Md. Business: Infectious diseases Hired: Dale VanderPutten as CEO, formerly CSO of DirectGene Inc. WIR...
BioCentury | Jul 22, 2002
Company News

DirectGene, GenVec deal

...cancer therapeutics based on selectively replicating adenovectors. The deal combines GNVC’s targeted adenovector technology with DirectGene’s...
...royalties. DirectGene will have rights to use the targeting technology with three of DirectGene’s adenovectors. DirectGene Inc....
BioCentury | Jul 15, 2002
Company News

GenVec, DirectGene cancer deal

...cancer therapeutics based on selectively replicating adenovectors. The deal combines GNVC's targeted adenovector technology with DirectGene's...
...royalties. DirectGene (Annapolis, Md.) will have rights to use the targeting technology with three of DirectGene's...
BioCentury | Jan 28, 2002
Company News

DirectGene, Intradigm deal

...combines Intradigm's gene vector technology with DirectGene's tumor-selective promoter technology. DirectGene will provide research funding. DirectGene Inc....
BioCentury | Jan 25, 2002
Company News

Intradigm, DirectGene cancer R&D deal

...Intradigm (Rockville, Md.) and DirectGene (Annapolis, Md.). partnered to develop cancer products. The deal combines Intradigm's...
...develop cancer products. The deal combines Intradigm's gene vector technology with DirectGene's tumor-selective promoter technology. DirectGene...
BioCentury | Feb 5, 2001
Finance

Ebb & Flow

...E 12.5 on the week after announcing a deal to manufacture clinical grade batches of DirectGene's...
BioCentury | Feb 5, 2001
Finance

Ebb & Flow

...E 12.5 on the week after announcing a deal to manufacture clinical grade batches of DirectGene's...
BioCentury | Feb 5, 2001
Company News

Crucell, DirectGene deal

...CRXL will manufacture clinical grade batches of DirectGene’s adeno-viral therapy for prostate cancer, which is expected...
...agreement giving DirectGene access to the PER.C6 technology. Crucell N.V. (Euronext:CRXL; CRXL), Leiden, the Netherlands DirectGene Inc....
BioCentury | Jan 31, 2001
Company News

First PER.C6 production deal for Crucell

...Gene and antibody company Crucell (CRXL; Euronext:CRXL) will manufacture clinical grade batches of DirectGene's compound to...
...its PER.C6 human cell line production platform. Last year, CRXL entered a license agreement giving DirectGene...
Items per page:
1 - 9 of 9